An Integrated Nanotechnology-Enabled Transbronchial Image-Guided Intervention Strategy for Peripheral Lung Cancer.
An Integrated Nanotechnology-Enabled Transbronchial Image-Guided Intervention Strategy for Peripheral Lung Cancer.
复制标题
DOI：
10.1158/0008-5472.can-15-3196
复制
发表时间：
2016-10-01
期刊：
影响因子：
11.2
通讯作者：
Yasufuku K
中科院分区：
文献类型：
--
作者：
Jin CS;Wada H;Anayama T;McVeigh PZ;Hu HP;Hirohashi K;Nakajima T;Kato T;Keshavjee S;Hwang D;Wilson BC;Zheng G;Yasufuku K
早期周围型肺癌的早期发现和有效治疗方式至关重要。目前对周围型肺癌的非手术治疗显示出与各种并发症相关的严重局限性，需要替代的微创治疗。在临床前动物模型中开发并证明了周围型肺癌的卟啉体纳米粒子启用的荧光引导的经支气管光热疗法（PTT）。全身给药的卟啉囊泡在肺肿瘤中积累，疾病与正常组织的对比度显著增强，这在小鼠原位人肺癌异种移植物的三种亚型（A549、H460和H520）和兔原位VX 2肿瘤中得到证实。内部原型荧光支气管镜证明了卟啉囊泡用于粘膜/粘膜下层肺肿瘤体内成像的能力，为经支气管PTT提供实时荧光指导。卟啉囊泡还显著增强了经支气管PTT的功效，并在兔模型中导致选择性和有效的肿瘤组织消融。临床使用的圆柱形扩散纤维成功地实现了肿瘤特异性热消融，显示了这种新型平台的临床转化对早期周围型肺癌的非手术治疗产生影响的有希望的证据。
Early detection and efficient treatment modality of early-stage peripheral lung cancer is essential. Current non-surgical treatments for peripheral lung cancer show critical limitations associated with various complications, requiring alternative minimally invasive therapeutics. Porphysome nanoparticle-enabled fluorescence-guided transbronchial photothermal therapy (PTT) of peripheral lung cancer was developed and demonstrated in preclinical animal models. Systemically-administered porphysomes accumulated in lung tumors with significantly enhanced disease-to-normal tissue contrast, as confirmed in three subtypes of orthotopic human lung cancer xenografts (A549, H460 and H520) in mice and in an orthotopic VX2 tumor in rabbits. An in-house prototype fluorescence bronchoscope demonstrated the capability of porphysomes for in vivo imaging of lung tumors in the mucosal/submucosal layers, providing real-time fluorescence guidance for transbronchial PTT. Porphysomes also enhanced the efficacy of transbronchial PTT significantly and resulted in selective and efficient tumor tissue ablation in the rabbit model. A clinically used cylindrical diffuser fiber successfully achieved tumor-specific thermal ablation, showing promising evidence for the clinical translation of this novel platform to impact upon non-surgical treatment of early-stage peripheral lung cancer.